Results 11 to 20 of about 409,524 (305)
Prognostic biomarkers of cutaneous melanoma [PDF]
Photodermatology, Photoimmunology & Photomedicine, 2022 AbstractBackground/purposeMelanomas account for only approximately 4% of diagnosed skin cancers in the United States but are responsible for the majority of deaths caused by skin cancer. Both genetic factors and ultraviolet (UV) radiation exposure play a role in the development of melanoma.
Liang, Ding +6 more
openaire +2 more sources
NR2F6 as a Prognostic Biomarker in HNSCC [PDF]
International Journal of Molecular Sciences, 2020 Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an immune checkpoint molecule in tumor-infiltrating T lymphocytes and is associated with a poor prognostic outcome in various cancers.
Luise Klapper +10 more
openaire +3 more sources
Prognostic Biomarkers for Melanoma Immunotherapy [PDF]
Current Oncology Reports, 2020 Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy.Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor.
Twitty, Christopher G +2 more
openaire +4 more sources
Prognostic and Predictive Biomarkers in Gliomas [PDF]
International Journal of Molecular Sciences, 2021 Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize the therapeutic approach to the patient and reveal new points of treatment options. Moreover, the 2021 World Health Organization Classification of Tumors of the Central Nervous System has fundamentally ...
Paulina Śledzińska +4 more
openaire +2 more sources
Prognostic biomarkers in osteoarthritis [PDF]
Current Opinion in Rheumatology, 2013 Identification of patients at risk for incident disease or disease progression in osteoarthritis remains challenging, as radiography is an insensitive reflection of molecular changes that presage cartilage and bone abnormalities. Thus there is a widely appreciated need for biochemical and imaging biomarkers.
Mukundan, Attur +3 more
openaire +2 more sources
The Journal of Pathology: Clinical Research, 2021 Immune cell infiltration has been identified as a prognostic biomarker in several cancers. However, no immune based biomarker has yet been validated for use in pancreatic ductal adenocarcinoma (PDAC). We undertook a systematic review and meta‐analysis of
Andrew J McGuigan +6 more
doaj +1 more source
A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer
Frontiers in Oncology, 2021 AimsDysregulated long noncoding RNAs (lncRNAs) contributing to ovarian cancer (OC) development may serve as prognostic biomarker. We aimed to explore a lncRNA signature to serve as prognostic biomarker of OC.MethodsUnivariate Cox regression was conducted
Hui Li +13 more
doaj +1 more source
Prognostic value of miR-21 in various cancers: an updating meta-analysis. [PDF]
PLoS ONE, 2014 Recently, more and more studies investigated the value of microRNA (miRNA) as a diagnostic or prognostic biomarker in various cancers. MiR-21 was found dysregulated in almost all types of cancers.
Xin Zhou +6 more
doaj +1 more source
The prognostic value of biomarkers in stroke [PDF]
Immunity & Ageing, 2016 Ischemic injury triggers inflammatory cascades and changes in the protein synthesis, neurotransmitters and neuro-hormones in the brain parenchyma that may further amplify the tissue damage. The "Triage® Stroke Panel", a biochemical multimarker assay, detects Brain Natriuretic Peptide (BNP), D-Dimers (DD), Matrix-Metalloproteinase-9 (MMP-9), and S100β ...
Iemolo F +4 more
openaire +2 more sources
Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. [PDF]
, 2012 BackgroundThe advent of personalized medicine requires robust, reproducible biomarkers that indicate which treatment will maximize therapeutic benefit while minimizing side effects and costs.
Boutros, Paul C +8 more
core +2 more sources